TY - JOUR
T1 - Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies
AU - Matsuzaki, Juntaro
AU - Suzuki, Hidekazu
AU - Nishizawa, Toshihiro
AU - Hirata, Kenro
AU - Tsugawa, Hitoshi
AU - Saito, Yoshimasa
AU - Okada, Sawako
AU - Fukuhara, Seiichiro
AU - Hibi, Toshifumi
PY - 2012/3
Y1 - 2012/3
N2 - Sitafloxacin-based triple therapy achieved 83.6% (per-protocol) and 78.2% (intention-to-treat) success in eradicating Helicobacter pylori among 78 Japanese patients after clarithromycin-based first-line and metronidazole-based second-line triple therapies failed. Eradication succeeded in 32 out of 43 patients, even with gyrA mutation-positive Helicobacter pylori (per protocol). The position of the gyrA mutation (N87 or D91) was determined to be a better marker than MIC levels for predicting outcomes of sitafloxacin-based treatment.
AB - Sitafloxacin-based triple therapy achieved 83.6% (per-protocol) and 78.2% (intention-to-treat) success in eradicating Helicobacter pylori among 78 Japanese patients after clarithromycin-based first-line and metronidazole-based second-line triple therapies failed. Eradication succeeded in 32 out of 43 patients, even with gyrA mutation-positive Helicobacter pylori (per protocol). The position of the gyrA mutation (N87 or D91) was determined to be a better marker than MIC levels for predicting outcomes of sitafloxacin-based treatment.
UR - http://www.scopus.com/inward/record.url?scp=84863394554&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863394554&partnerID=8YFLogxK
U2 - 10.1128/AAC.05941-11
DO - 10.1128/AAC.05941-11
M3 - Article
C2 - 22203601
AN - SCOPUS:84863394554
SN - 0066-4804
VL - 56
SP - 1643
EP - 1645
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 3
ER -
